Paratek Pharmaceuticals, Inc. (PRTK): Richard J. Lim , director of Paratek Pharmaceuticals, Inc. purchased 461,538 shares on Jun 27, 2016. The Insider buying transaction was reported by the company on Jun 29, 2016 to the Securities and Exchange Commission. The shares were purchased at $13.00 per share for a total value of $5,999,994.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 27, 2016, Michael Bigham (CEO) purchased 20,000 shares at $13.45 per share price.On Dec 14, 2015, Evan Loh (President and CMO) purchased 2,300 shares at $16.83 per share price.Also, On Jun 1, 2015, Healthcare Investments (ca Hbm (10% owner) sold 20,580 shares at $30.86 per share price.
Shares of Paratek Pharmaceuticals Inc (PRTK) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -0.34 points or -2.64% at $12.52 with 4,48,335 shares getting traded. Post opening the session at $12.83, the shares hit an intraday low of $12.05 and an intraday high of $13.095 and the price vacillated in this range throughout the day. The company has a market cap of $222 M and the number of outstanding shares has been calculated to be 1,77,40,211 shares. The 52-week high of Paratek Pharmaceuticals Inc is $28.74 and the 52-week low is $12.05.
Company has been under the radar of several Street Analysts.Paratek Pharmaceuticals Inc is Reiterated by H.C. Wainwright to Buy and the brokerage firm has raised the Price Target to $ 34 from a previous price target of $31 .The Rating was issued on Jun 17, 2016.Paratek Pharmaceuticals Inc is Initiated by Robert W. Baird to Outperform and the brokerage firm has set the Price Target at $30. The Rating was issued on May 13, 2016.
Paratek Pharmaceuticals Inc. (Paratek) formerly Transcept Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI) and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily tetracycline-derived compound designed for use in the treatment of acne and rosacea.